Cellular Biomedicine Group, Inc.
DelistedCIK 1378624fmd_1W37T9GK5H564SX5RKKAPKYB7XManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Sep 30, 2020, 42 periods
Latest annual · FY2019
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (51)
- Net income
- (50)
- Free cash flow
- (50)
Latest quarter · Q3 FY2020
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (18)
- Net income
- (17)
Bulls and bears
Loading
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
AI-written
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2016 to FY2019
- -18.5%
- Revenue, 5 yearsFY2014 to FY2019
- -9.6%
- Net income, 5 yearsFY2014 to FY2019
- n/m
Cellular Biomedicine Group, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Revenue | $339,920 | $224,403 | +51.5% | 10-K 2020-02-28 · proof |
| Gross profit | $277,542 | $88,642 | +213.1% | 10-K 2020-02-28 · proof |
| Operating income | -$51 million | -$40.5 million | 10-K 2020-02-28 · proof | |
| Net income | -$50 million | -$38.9 million | 10-K 2020-02-28 · proof | |
| Cash from operating activities | -$39.6 million | -$25.1 million | 10-K 2020-02-28 · proof | |
| Free cash flow | -$50.3 million | -$31.7 million | 10-K 2020-02-28 · proof | |
| Total assets | $97.3 million | $107.6 million | -9.5% | 10-K 2020-02-28 · proof |
| Total liabilities | $41.6 million | $22.4 million | +86.1% | 10-K 2020-02-28 · proof |
| Cash and cash equivalents | $0 | $52.8 million | -100% | 10-Q 2020-11-09 · proof |
- What was Cellular Biomedicine Group, Inc.'s revenue in fiscal 2019?
- Cellular Biomedicine Group, Inc. reported revenue of $339,920 for fiscal 2019 (the year ended Dec 31, 2019), against $224,403 the year before (+51.5%). Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What was Cellular Biomedicine Group, Inc.'s gross profit in fiscal 2019?
- Cellular Biomedicine Group, Inc. reported gross profit of $277,542 for fiscal 2019 (the year ended Dec 31, 2019), against $88,642 the year before (+213.1%). Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What was Cellular Biomedicine Group, Inc.'s operating income in fiscal 2019?
- Cellular Biomedicine Group, Inc. reported operating income of -$51 million for fiscal 2019 (the year ended Dec 31, 2019), against -$40.5 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What was Cellular Biomedicine Group, Inc.'s net income in fiscal 2019?
- Cellular Biomedicine Group, Inc. reported net income of -$50 million for fiscal 2019 (the year ended Dec 31, 2019), against -$38.9 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What was Cellular Biomedicine Group, Inc.'s cash from operating activities in fiscal 2019?
- Cellular Biomedicine Group, Inc. reported cash from operating activities of -$39.6 million for fiscal 2019 (the year ended Dec 31, 2019), against -$25.1 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What was Cellular Biomedicine Group, Inc.'s free cash flow in fiscal 2019?
- Cellular Biomedicine Group, Inc. reported free cash flow of -$50.3 million for fiscal 2019 (the year ended Dec 31, 2019), against -$31.7 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What are Cellular Biomedicine Group, Inc.'s total assets?
- As of Dec 31, 2019, Cellular Biomedicine Group, Inc. reported total assets of $97.3 million, against $107.6 million a year earlier (-9.5%). Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What are Cellular Biomedicine Group, Inc.'s total liabilities?
- As of Dec 31, 2019, Cellular Biomedicine Group, Inc. reported total liabilities of $41.6 million, against $22.4 million a year earlier (+86.1%). Source: the 10-K filed with the SEC on Feb 28, 2020. SEC
- What are Cellular Biomedicine Group, Inc.'s cash and cash equivalents?
- As of Dec 31, 2019, Cellular Biomedicine Group, Inc. reported cash and cash equivalents of $0, against $52.8 million a year earlier (-100%). Source: the 10-Q filed with the SEC on Nov 9, 2020. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1378624&period_type=annual&limit=5"Information only, not investment advice.